Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

LAG3 ectodomain structure reveals functional interfaces for ligand and antibody recognition
Qianqian Ming, Daiana P. Celias, Chao Wu, et al.
Nature Immunology (2022) Vol. 23, Iss. 7, pp. 1031-1041
Open Access | Times Cited: 49

Showing 1-25 of 49 citing articles:

LAG-3 as the third checkpoint inhibitor
Vaishali Aggarwal, Creg J. Workman, Dario A.A. Vignali
Nature Immunology (2023) Vol. 24, Iss. 9, pp. 1415-1422
Open Access | Times Cited: 157
LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
Nicole Joller, Ana C. Anderson, Vijay K. Kuchroo
Immunity (2024) Vol. 57, Iss. 2, pp. 206-222
Open Access | Times Cited: 52
The immune checkpoint receptor LAG3: Structure, function, and target for cancer immunotherapy
Roy A. Mariuzza, Salman Shahid, S.S. Karade
Journal of Biological Chemistry (2024) Vol. 300, Iss. 5, pp. 107241-107241
Open Access | Times Cited: 24
Immune checkpoint inhibitors: breakthroughs in cancer treatment
Xueqing Kong, Jinyi Zhang, Shuwei Chen, et al.
Cancer Biology and Medicine (2024), pp. 1-11
Open Access | Times Cited: 24
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Nanhao Yin, Xintong Li, Xuanwei Zhang, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 20
Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of signaling motifs
Yong Jiang, Anran Dai, Yuwei Huang, et al.
Cell (2025)
Open Access | Times Cited: 3
Cutting-Edge: Preclinical and Clinical Development of the First Approved Lag-3 Inhibitor
Luisa Chocarro, Ana Bocanegra, Ester Blanco, et al.
Cells (2022) Vol. 11, Iss. 15, pp. 2351-2351
Open Access | Times Cited: 57
Structural insights reveal interplay between LAG-3 homodimerization, ligand binding, and function
John L. Silberstein, Jasper Du, Kun‐Wei Chan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 12
Open Access | Times Cited: 14
Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein
Xiaobo Mao, Hao Gu, Donghoon Kim, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 10
Cutting Edge: LAG3 Dimerization Is Required for TCR/CD3 Interaction and Inhibition of Antitumor Immunity
Kieran Adam, Zhanna Lipatova, Maria Abdul Ghafoor Raja, et al.
The Journal of Immunology (2024) Vol. 213, Iss. 1, pp. 7-13
Closed Access | Times Cited: 6
Regulatory T cells as crucial trigger and potential target for hyperprogressive disease subsequent to PD-1/PD-L1 blockade for cancer treatment
Zhe Ren, Kaiqing Yang, Lin Zhu, et al.
International Immunopharmacology (2024) Vol. 132, pp. 111934-111934
Closed Access | Times Cited: 5
Shedding light on the role of LAG-3 in hepatocellular carcinoma: unraveling immunomodulatory pathways
Konstantinos Arvanitakis, Stavros P. Papadakos, Georgios Vakadaris, et al.
Hepatoma Research (2024)
Open Access | Times Cited: 5
Modulating α-synuclein propagation and decomposition: Implications in Parkinson's disease therapy
Beining Li, Xue Xiao, Mingxia Bi, et al.
Ageing Research Reviews (2024) Vol. 98, pp. 102319-102319
Closed Access | Times Cited: 5
LAG‐3—An incompletely understood target in cancer therapy
Judith Leitner, Katharina Radakovics, Peter Steinberger
The FASEB Journal (2024) Vol. 38, Iss. 22
Open Access | Times Cited: 5
Simultaneous inhibition of PD-1 and LAG-3: the future of immunotherapy?
Sasha-Jane Abi-Aad, Joseph Zouein, Antoine Chartouni, et al.
Immunotherapy (2023) Vol. 15, Iss. 8, pp. 611-618
Closed Access | Times Cited: 12
Advancement of anti‐LAG‐3 in cancer therapy
Yunong Li, Mingyi Ju, Yuxi Miao, et al.
The FASEB Journal (2023) Vol. 37, Iss. 11
Closed Access | Times Cited: 11
Prognostic significance of Lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis
Rongyang Li, Jianhao Qiu, Zhan Zhang, et al.
Cancer Cell International (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Development of LAG-3/FGL1 blocking peptide and combination with radiotherapy for cancer immunotherapy
Yuzhen Qian, Yixuan Sun, Peishang Shi, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 3, pp. 1150-1165
Open Access | Times Cited: 11
Lysosome‐Targeting Bacterial Outer Membrane Vesicles for Tumor Specific Degradation of PD‐L1
Panpan Ji, Pengying Wu, Lantian Wang, et al.
Small (2024) Vol. 20, Iss. 43
Closed Access | Times Cited: 4
Structural basis for mouse LAG3 interactions with the MHC class II molecule I-Ab
Qianqian Ming, Daniel Antfolk, David A. Price, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 4
LAG Time in the Era of Immunotherapy—New Molecular Insights Into the Immunosuppression Mechanism of Lymphocyte Activation Gene‐3
Vincent C. Luca
Immunological Reviews (2025) Vol. 330, Iss. 1
Closed Access
Development of Novel Peptide-Based Radiotracers for Detecting FGL1 Expression in Tumors
Yue Xu, Jinyuan Zhang, Donghui Pan, et al.
Molecular Pharmaceutics (2025)
Closed Access
Unusual traits shape the architecture of the Ig ancestor molecule
Alejandro Urdiciain, Thomas Madej, Jiyao Wang, et al.
Communications Biology (2025) Vol. 8, Iss. 1
Open Access
Fibrinogen‐like 1: A hepatokine linking liver physiology to hematology
Jean Personnaz, Hervé Guillou, Léon Kautz
HemaSphere (2024) Vol. 8, Iss. 7
Open Access | Times Cited: 3
Advances in LAG3 cancer immunotherapeutics
Kieran Adam, Samuel C. Butler, Creg J. Workman, et al.
Trends in cancer (2024)
Closed Access | Times Cited: 3
Page 1 - Next Page

Scroll to top